Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018591383> ?p ?o ?g. }
- W2018591383 endingPage "1053" @default.
- W2018591383 startingPage "1044" @default.
- W2018591383 abstract "Abstract CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensifi-cation. Among 901 patients under age 21 years, 5-year survival was 52%, and event-free survival was 42%. Survival improved from 44% between 1996 and 1998 to 58% between 2000 and 2002 (P = .005), and treatment-related mortality declined from 19% to 12% (P = .025). Partial replacement of daunomycin with idarubicin in the 5-drug induction combination achieved a remission rate of 88%, similar to historical controls. Postremission survival was 56% in patients randomized to either 5-drug reinduction or fludarabine/cytarabine/idarubicin. For patients with or without a related donor, respective 5-year disease-free survival was 61% and 50% (P = .021); respective survival was 68% and 62% (P = .425). Donor availability conferred no benefit on those with inv(16) or t(8;21) cytogenetics. After cytarabine intensification, patients randomized to interleukin-2 or none experienced similar outcomes. Factors predictive of inferior survival were age more than 16 years, non-white ethnicity, absence of related donor, obesity, white blood cell count more than 100 000 × 109/L, −7/7q−, −5/5q−, and/or complex karyotype. No new agent improved outcomes; experience may have contributed to better results time." @default.
- W2018591383 created "2016-06-24" @default.
- W2018591383 creator A5008605349 @default.
- W2018591383 creator A5008703987 @default.
- W2018591383 creator A5018786888 @default.
- W2018591383 creator A5021003209 @default.
- W2018591383 creator A5021059238 @default.
- W2018591383 creator A5021705500 @default.
- W2018591383 creator A5022384366 @default.
- W2018591383 creator A5023734568 @default.
- W2018591383 creator A5025630600 @default.
- W2018591383 creator A5048397868 @default.
- W2018591383 creator A5052896867 @default.
- W2018591383 creator A5059528446 @default.
- W2018591383 creator A5066356637 @default.
- W2018591383 creator A5066861312 @default.
- W2018591383 creator A5074136109 @default.
- W2018591383 creator A5082967648 @default.
- W2018591383 date "2008-02-01" @default.
- W2018591383 modified "2023-10-16" @default.
- W2018591383 title "Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group" @default.
- W2018591383 cites W1586763410 @default.
- W2018591383 cites W1784548805 @default.
- W2018591383 cites W1819781110 @default.
- W2018591383 cites W1861929829 @default.
- W2018591383 cites W1925684361 @default.
- W2018591383 cites W1966019264 @default.
- W2018591383 cites W1966908478 @default.
- W2018591383 cites W1967891250 @default.
- W2018591383 cites W1974804829 @default.
- W2018591383 cites W1992371348 @default.
- W2018591383 cites W1993151769 @default.
- W2018591383 cites W1996553486 @default.
- W2018591383 cites W2016395017 @default.
- W2018591383 cites W2018895375 @default.
- W2018591383 cites W2019793347 @default.
- W2018591383 cites W2020904615 @default.
- W2018591383 cites W2022307983 @default.
- W2018591383 cites W2033765628 @default.
- W2018591383 cites W2034646423 @default.
- W2018591383 cites W2049310237 @default.
- W2018591383 cites W2053146576 @default.
- W2018591383 cites W2054817999 @default.
- W2018591383 cites W2054855188 @default.
- W2018591383 cites W2090798800 @default.
- W2018591383 cites W2091413129 @default.
- W2018591383 cites W2093979623 @default.
- W2018591383 cites W211185702 @default.
- W2018591383 cites W2120462605 @default.
- W2018591383 cites W2129856600 @default.
- W2018591383 cites W2133262115 @default.
- W2018591383 cites W2133432816 @default.
- W2018591383 cites W2140929964 @default.
- W2018591383 cites W2142316835 @default.
- W2018591383 cites W2148774731 @default.
- W2018591383 cites W2150113701 @default.
- W2018591383 cites W2158641730 @default.
- W2018591383 cites W2159289068 @default.
- W2018591383 cites W2161150935 @default.
- W2018591383 cites W2175893112 @default.
- W2018591383 cites W2187668060 @default.
- W2018591383 cites W2204551030 @default.
- W2018591383 cites W2274220969 @default.
- W2018591383 cites W2317674375 @default.
- W2018591383 cites W2327592010 @default.
- W2018591383 cites W2343385965 @default.
- W2018591383 cites W2406871555 @default.
- W2018591383 cites W2416628098 @default.
- W2018591383 cites W4239564692 @default.
- W2018591383 cites W4251239638 @default.
- W2018591383 cites W4293241248 @default.
- W2018591383 cites W4474461 @default.
- W2018591383 doi "https://doi.org/10.1182/blood-2007-04-084293" @default.
- W2018591383 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2214754" @default.
- W2018591383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18000167" @default.
- W2018591383 hasPublicationYear "2008" @default.
- W2018591383 type Work @default.
- W2018591383 sameAs 2018591383 @default.
- W2018591383 citedByCount "249" @default.
- W2018591383 countsByYear W20185913832012 @default.
- W2018591383 countsByYear W20185913832013 @default.
- W2018591383 countsByYear W20185913832014 @default.
- W2018591383 countsByYear W20185913832015 @default.
- W2018591383 countsByYear W20185913832016 @default.
- W2018591383 countsByYear W20185913832017 @default.
- W2018591383 countsByYear W20185913832018 @default.
- W2018591383 countsByYear W20185913832019 @default.
- W2018591383 countsByYear W20185913832020 @default.
- W2018591383 countsByYear W20185913832021 @default.
- W2018591383 countsByYear W20185913832022 @default.
- W2018591383 countsByYear W20185913832023 @default.
- W2018591383 crossrefType "journal-article" @default.
- W2018591383 hasAuthorship W2018591383A5008605349 @default.
- W2018591383 hasAuthorship W2018591383A5008703987 @default.
- W2018591383 hasAuthorship W2018591383A5018786888 @default.
- W2018591383 hasAuthorship W2018591383A5021003209 @default.
- W2018591383 hasAuthorship W2018591383A5021059238 @default.
- W2018591383 hasAuthorship W2018591383A5021705500 @default.